Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of nemiralisib in symptomatic COPD with prior exacerbations
2017-004564-35Phase 2Completed
- Sponsor
- GSK
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB) and emphysema comparing Nemiralisib with Placebo (2 arms). Primary endpoint: Annualized rate of on-treatment moderate and severe COPD exacerbations. Started May 2018; status: completed.
02
Drugs
nemiralisib
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)emphysema
Beyond the preview
Go deeper on 2017-004564-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004564-35.